REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system and neuropsychiatric disorders, with a lead pipeline candidate targeting schizophrenia and related conditions. The company entered the public markets in 2020 through its de-SPAC merger with Tenzing Acquisition Corp, a blank-check vehicle sponsored by Tenzing Global Management. RVPH remains listed on Nasdaq as an active post-merger public company operating in the healthcare and pharmaceutical sector, and filed its most recent Form 8-K with the SEC on May 13, 2026. For comprehensive SPAC deal data, filing history, and real-time company intelligence on RVPH, sign up for full access at SpacDesk.